Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Should Post-PCI Biomarkers Elevation Be of Concern?

Elevated markers after PCI in stable patients treated with the latest generation stents continues to happen. However, only the association between biomarker elevation with creatine kinase-myocardial band (CK-MB) should be of concern, sin it was associated with mortality at one year. Post procedural cardiac troponin (cTn) elevation was not associated to future events, according to this study recently published in J Am Coll Cardiol Intv.

This study explored the association between biomarker elevation and CK-MB or cTn following percutaneous coronary intervention (PCI) and mortality in patients undergoing PCI for stable angina with normal baseline values.

Several prior studies had associated increased Ck-Mb with increased mortality after procedure, but data on cTn is contradicting and scarce. 

In this study, the outcomes of 5 contemporary studies on DES and a large registry were looked at. It assessed mortality in stable patients with normal baseline biomarkers who presented biomarker elevation after programmed PCI vs. patients whose biomarkers remained normal. 


Read also: First Results for Ticagrelor in Elective Coronary Angioplasty.


The study looked at 13452 patients. There was 23.9% Ck-Mb elevation and 68.4% cTn elevation. Post elective PCI biomarker elevation resulted quite frequent, with nearly 1 every 4 patients for Ck-Mb and 3 every 4 for cTn.

In the patient cohort for whom both assays were available (n = 8,859), both biomarkers were elevated in 2.4% of patients (CK-MB ≥5 times over the normal values and cTn was ≥35 times over cutoff value) while 92% presented both below cutoff values.

Practically all patients showing elevated Ck-Mb also showed elevated cTn. However, the opposite was not true, nearly 65% of patients with elevated cTn showed normal Ck-Mb values.


Read also: Infective Endocarditis After TAVI.


Multivariable analysis showed that age, a history of acute myocardial infarction, lesion complexity, hyperlipidemia and Ck-Mb ratio ≥10 post-procedure were associated to increased mortality at one year. This was not the case for isolated cTn increase. 

Conclusion

Biomarker increase after elective PCI is very frequent. Increased Ck-Mb was associated to increased mortality at one year, but not increased cTn.

Original Title: Impact of Periprocedural Myocardial Biomarker Elevation on Mortality Following Elective Percutaneous Coronary Intervention.

Reference: Hector M. Garcia-Garcia et al. J Am Coll Cardiol Intv 2019;12:1954–62.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...